Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Adisseo, Beta Renewables, DONG Energy and Monsanto, and is a parent company of Novozymes Belgium BVBA, Novozymes BioAg Limited, Novozymes Canada Limited, Albumedix A/S and Organobalance GmbH, among others.
Industry, Sector and Symbol:
- Sector: Basic Materials
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:NVZMY
- CUSIP: N/A
- Web: www.novozymes.com
- Market Cap: $11.29649 billion
- Outstanding Shares: 296,961,000
- 50 Day Moving Avg: $44.58
- 200 Day Moving Avg: $41.09
- 52 Week Range: $31.57 - $49.25
Sales & Book Value:
- Trailing P/E Ratio: 29.03
- Foreward P/E Ratio: 26.01
- P/E Growth: 22.61
- Annual Revenue: $2.19 billion
- Price / Sales: 6.17
- Book Value: $5.66 per share
- Price / Book: 8.04
- Annual Dividend: $0.37
- Dividend Yield: 0.8%
- EBIDTA: $769.9 million
- Net Margins: 21.58%
- Return on Equity: 27.40%
- Return on Assets: 16.74%
- Current Ratio: 1.48%
- Quick Ratio: 0.92%
- Average Volume: 23,336 shs.
- Beta: 1.1
Frequently Asked Questions for Novozymes A/S (OTCMKTS:NVZMY)
What is Novozymes A/S's stock symbol?
Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMY."
How were Novozymes A/S's earnings last quarter?
Novozymes A/S (OTCMKTS:NVZMY) issued its earnings results on Thursday, August, 6th. The company reported $0.33 EPS for the quarter, missing analysts' consensus estimates of $0.35 by $0.02. Novozymes A/S had a net margin of 21.58% and a return on equity of 27.40%. View Novozymes A/S's Earnings History.
Where is Novozymes A/S's stock going? Where will Novozymes A/S's stock price be in 2017?
4 analysts have issued 1-year price objectives for Novozymes A/S's shares. Their predictions range from $47.50 to $47.50. On average, they anticipate Novozymes A/S's stock price to reach $47.50 in the next year. View Analyst Ratings for Novozymes A/S.
Who are some of Novozymes A/S's key competitors?
Some companies that are related to Novozymes A/S include Anglo Amer Adr (NGLOY), Nucor Corporation (NUE), Freeport-McMoran (FCX), Barrick Gold Corporation (ABX), Newmont Mining Corporation (NEM), ThyssenKrupp AG (TYEKF), UPM-Kymmene Corp. (UPMKY), Potash Corporation of Saskatchewan (POT), Westrock Company (WRK), Fresnillo PLC (FNLPF), Anglo American plc (AAL), Celanese Corporation (CE), Agrium (AGU), Koninklijke DSM NV (RDSMY), Franco-Nevada Corporation (FNV), Albemarle Corporation (ALB), Vedanta Limited (VEDL) and Eastman Chemical Company (EMN).
Who are Novozymes A/S's key executives?
Novozymes A/S's management team includes the folowing people:
- Joergen Buhl Rasmussen, Chairman of the Board
- Peder Holk Nielsen, President, Chief Executive Officer
- Agnete Raaschou-Nielsen, Vice Chairman of the Board
- Benny D. Loft, Executive Vice President, Corporate Functions; Chief Financial Officer
- Thomas Videbaek, Chief Operating Officer; Executive Vice President, Research, Innovation & Supply
- Andrew Fordyce, Executive Vice President, Food & Beverages
- Anders Lund, Executive Vice President, Household Care & Technical
- Tina Sejersgaard Fanoe, Executive Vice President, Agriculture & Bioenergy
- Lena Bech Halskov, Director, Employee Representative
- Lars Hall Green, Director
How do I buy Novozymes A/S stock?
Shares of Novozymes A/S can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novozymes A/S's stock price today?
MarketBeat Community Rating for Novozymes A/S (OTCMKTS NVZMY)MarketBeat's community ratings are surveys of what our community members think about Novozymes A/S and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Novozymes A/S stock can currently be purchased for approximately $45.52.
Consensus Ratings for Novozymes A/S (OTCMKTS:NVZMY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 2 Hold Ratings, 1 Buy Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||$47.50|
Analysts' Ratings History for Novozymes A/S (OTCMKTS:NVZMY)
(Data available from 7/21/2015 forward)
|5/10/2017||Jefferies Group LLC||Reiterated Rating||Hold||$47.50|
|2/10/2017||J P Morgan Chase & Co||Downgrade||Overweight -> Neutral|
|1/5/2017||Sanford C. Bernstein||Upgrade||Mkt Perform -> Outperform|
|9/27/2016||Berenberg Bank||Initiated Coverage||Sell|
|1/20/2016||Goldman Sachs Group, Inc. (The)||Upgrade||Sell -> Neutral|
|8/7/2015||Nordea Equity Research||Downgrade||Buy -> Hold|
Earnings History for Novozymes A/S (OTCMKTS:NVZMY)Earnings History by Quarter for Novozymes A/S (OTCMKTS NVZMY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Novozymes A/S (OTCMKTS:NVZMY)
Current Year EPS Consensus Estimate: $1.61 EPS
Next Year EPS Consensus Estimate: $1.75 EPS
Dividend History for Novozymes A/S (OTCMKTS:NVZMY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Novozymes A/S (OTCMKTS:NVZMY)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Novozymes A/S (OTCMKTS:NVZMY)
Latest Headlines for Novozymes A/S (OTCMKTS:NVZMY)
Novozymes A/S (NVZMY) Chart for Friday, July, 21, 2017